Depletes Folic Acid. This medication is commonly used for Hypertension
Calcium channel blockers (CCBs), particularly nifedipine, can cause gum tissue overgrowth (gingival hyperplasia) in both men and women. Studies suggest a dose-dependent link with CCBs potentially doubling the risk. Studies also confirm a link between CCB use (like amlodipine and nifedipine) and gingival hyperplasia, even beyond factors like poor hygiene. Research suggests impaired folate uptake in gum tissue might be another key contributor. Supplementation with folate to help protect against CCB-induced hyperplasia may be beneficial.
Brown RS, Sein P, Corio R, Bottomley WK. Nitrendipine-induced gingival hyperplasia. First case report. Oral Surg Oral Med Oral Pathol. 1990 Nov;70(5):593-6. Damdoum M, Varma SR, Nambiar M, Venugopal A. Calcium Channel Blockers Induced Gingival Overgrowth: A Comprehensive Review from a Dental Perspective. J Int Soc Prev Community Dent. 2022 Jun 29;12(3):309-322. Joshi S, Bansal S. A rare case report of amlodipine-induced gingival enlargement and review of its pathogenesis. Case Rep Dent. 2013;2013:138248. Lawrence DB, Weart CW, Laro JJ, Neville BW. Calcium channel blocker-induced gingival hyperplasia: case report and review of this iatrogenic disease. J Fam Pract. 1994 Nov;39(5):483-8. Livada R, Shiloah J. Calcium channel blocker-induced gingival enlargement. J Hum Hypertens. 2014 Jan;28(1):10-4. Madi M, Shetty SR, Babu SG, Achalli S. Amlodipine-induced Gingival Hyperplasia - A Case Report and Review. West Indian Med J. 2015 Jun;64(3):279-82.
Folate (.2mg as L-5-Methylfolate) — 0.34 DFE
Low folate status contributes to elevated homocysteine, a metabolite that has been associated with endothelial dysfunction, arterial stiffness, and a higher risk of stroke and coronary heart disease. Large observational studies consistently show that individuals with higher homocysteine levels have greater rates of cardiovascular events, and folate intake is one of the key nutritional determinants of homocysteine. Clinically, folic acid supplementation (often combined with vitamins B6 and B12) can lower homocysteine and appears to modestly reduce stroke risk in some populations, making the identification and correction of folate deficiency an important part of broader cardiovascular risk reduction.
Folate deficiency in the periconceptional period significantly increases the risk of neural tube defects (NTDs) such as spina bifida and anencephaly, because adequate folate is required for proper closure of the embryonic neural tube in the first month of pregnancy. Large observational datasets and randomized trials have shown that appropriate folic acid supplementation before conception and in early pregnancy can reduce NTD risk by roughly 50–70% in the general population, with even greater risk reduction in women with a prior NTD‑affected pregnancy. The practical implication is that all women of childbearing potential, not just those actively planning pregnancy, are typically advised to maintain adequate daily folic acid intake so that red‑cell folate stores are sufficient well before conception occurs.
Folate deficiency has been associated with a higher risk of depressive symptoms, irritability, and other mood disturbances, likely through its role in one‑carbon metabolism, monoamine neurotransmitter synthesis, and methylation processes in the brain. Clinical and epidemiologic studies have found that people with low folate or elevated homocysteine are more likely to experience major depression, and lower folate status has been linked to poorer response to certain antidepressant medications. The encouraging clinical point is that, in folate‑deficient individuals, correcting folate status (often with folic acid or methylfolate, and alongside vitamin B12 when indicated) may improve mood symptoms and, in some cases, enhance antidepressant treatment response, especially when combined with comprehensive psychiatric and lifestyle interventions.
Folate (folic acid) deficiency impairs DNA synthesis in rapidly dividing cells, which leads to megaloblastic anemia characterized by enlarged red blood cells, fatigue, pallor, and sometimes shortness of breath. Population studies have shown that folate deficiency and macrocytosis can be present for months before overt symptoms appear, and in some cohorts, up to roughly one quarter of anemic adults had an underlying folate or B12 deficiency rather than iron deficiency alone. The encouraging clinical point is that, once identified, folate‑responsive megaloblastic anemia often improves within weeks of adequate folic acid repletion, with reticulocyte counts rising in about 5–7 days and hemoglobin recovering more gradually over several weeks.